News
Genethon gets UK MHRA nod to initiate pivotal phase 3 trial of GNT0004, a low-dose microdystrophin gene therapy for Duchenne muscular dystrophy: Paris, France Wednesday, July 30, ...
OncoZenge AB (publ) ("OncoZenge" or "the Company") today announced a comprehensive market and strategy update after successfully securing full funding for its BupiZenge Phase 3 clinical trial aimed at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback